Drug Profile
Pudexacianinium - Astellas Pharma
Alternative Names: ASP-5354; ASP5354-chloride; Pudexacianinium chloride - Astellas PharmaLatest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Mie University; Nagoya University
- Developer Astellas Pharma
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Unspecified
- Phase II Breast cancer; Malignant melanoma
Most Recent Events
- 15 Dec 2023 Astellas Pharma terminates a phase II trial in Malignant melanoma (Diagnosis) in USA (Intratumoural) due to the company's strategic decision (NCT05457842)
- 15 Dec 2023 Astellas Pharma terminates a phase II trial in Breast cancer (Diagnosis) in USA (Intratumoural) due to the company's strategic decision (NCT05457842)
- 15 Dec 2023 Astellas Phatma terminates a phase II trial in Breast cancer (Diagnosis) in USA (SC) due to the company's strategic decision (NCT05457842)